Clinical Trials List
2018-10-17 - 2024-08-31
Phase III
Terminated4
ICD-9151.9
Malignant neoplasm of stomach, unspecified
-
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/15
Investigators and Locations
Co-Principal Investigator
- Yan-Shen Shan Division of General Surgery
- Shang-Yin Wu Division of Hematology & Oncology
- 趙盈瑞 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Audit
None
Co-Principal Investigator
- 吳佳哲 Division of Hematology & Oncology
- 曾亮節 Division of Radiology
- Yu-Li Su Division of Hematology & Oncology
- Shau-Hsuan Li Division of Hematology & Oncology
- 劉建廷 Division of Hematology & Oncology
- Tai-Jan Chiu Division of Hematology & Oncology
- 陳彥豪 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 張端瑩 Division of Hematology & Oncology
- 林育麟 Division of Hematology & Oncology
- YU-YUN SHAO Division of Hematology & Oncology
- TA-CHEN HUANG Division of Hematology & Oncology
- Ann-Lii Cheng Division of Hematology & Oncology
- 林宗哲 Division of Hematology & Oncology
- Ying-Chun Shen Division of Hematology & Oncology
- 陳國興 Division of Hematology & Oncology
- Chih-Hung Hsu Division of Hematology & Oncology
- 梁逸歆 Division of Hematology & Oncology
- JHE-CYUAN GUO Division of Hematology & Oncology
- 呂理駿 Division of Hematology & Oncology
- Chia-Chi Lin Division of Hematology & Oncology
- Chiun Hsu Division of Hematology & Oncology
- Hsiang-Fong Kao Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Study Contacts
- -
Audit
None
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
28 participants
-
Global
780 participants
